Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

REVB

Revelation Biosciences Inc

Oct 08 • 01:58PM ET

0.8149

Dollar change +0.0249
Percentage change 3.15	%

Healthcare • Biotechnology • USA • NASD

Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-28.44	Insider Own	0.18%	Shs Outstand	3.76M	Perf Week	-2.79%
Market Cap	3.06M	Forward P/E	-	EPS next Y	-5.57	Insider Trans	0.00%	Shs Float	3.75M	Perf Month	-7.39%
Income	-15.90M	PEG	-	EPS next Q	-2.84	Inst Own	1.34%	Short Float	0.68%	Perf Quarter	-54.22%
Sales	0.00M	P/S	-	EPS this Y	-2047.17%	Inst Trans	46.34%	Short Ratio	0.02	Perf Half Y	-66.46%
Book/sh	0.69	P/B	1.17	EPS next Y	51.10%	ROA	-112.35%	Short Interest	0.03M	Perf Year	-95.99%
Cash/sh	3.21	P/C	0.25	EPS next 5Y	-	ROE	-253.32%	52W Range	0.70 - 25.26	Perf YTD	-94.57%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-1394.44%	52W High	-96.77%	Beta	0.17
Dividend TTM	-	Quick Ratio	1.10	Sales past 5Y	0.00%	Gross Margin	-	52W Low	16.09%	ATR (14)	0.10
Dividend Ex-Date	-	Current Ratio	1.10	EPS Y/Y TTM	19.48%	Oper. Margin	0.00%	RSI (14)	42.97	Volatility	6.33% 8.97%
Employees	9	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	14.45
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	31.36%	Payout	-	Rel Volume	0.07	Prev Close	0.79
Sales Surprise	-	EPS Surprise	-184.21%	Sales Q/Q	-	Earnings	Aug 09 AMC	Avg Volume	1.61M	Price	0.81
SMA20	-2.94%	SMA50	-19.24%	SMA200	-76.64%	Trades		Volume	80,768	Change	3.15%

Sep-24-24 06:00AM	Revelation Biosciences' Gemini Induces Dose Dependent Significant Increases in IL-10 (Business Wire)
Aug-21-24 05:30PM	Revelation Biosciences Inc. Announces Exercise of Warrants for $3.8 Million in Gross Proceeds (Business Wire) +101.27% -40.19%
Aug-09-24 09:53PM	REVB Stock Earnings: Revelation Biosciences Misses EPS for Q2 2024 (InvestorPlace) -7.68%
04:15PM	Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2024 (Business Wire)
Jun-24-24 09:00AM	Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity (Business Wire) +13.74%
09:21AM	Loading…
Jun-13-24 09:21AM	Revelation Biosciences Has Completed Dosing of its First in Human Phase 1 Clinical Study of Gemini (Business Wire)
May-10-24 09:53PM	REVB Stock Earnings: Revelation Biosciences Misses EPS for Q1 2024 (InvestorPlace) -6.36% -10.68%
04:52PM	Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024 (Business Wire)
Mar-22-24 09:52PM	REVB Stock Earnings: Revelation Biosciences Beats EPS for Q4 2023 (InvestorPlace)
04:15PM	Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023 (Business Wire)
Mar-13-24 09:00AM	Revelation Biosciences Inc. Gives Oral Presentation at Advances in Critical Care Nephrology (AKI & CRRT 2024) (Business Wire) -16.67%
Mar-12-24 09:00AM	Revelation Biosciences Inc. to Participate in a Virtual Fireside Chat at the 36th Annual Roth Conference (Business Wire) -7.14%
Mar-04-24 09:00AM	Revelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of Gemini (Business Wire) -6.32%
Feb-13-24 09:00AM	Revelation Biosciences Inc. Receives Invitation to Give an Oral Presentation at The 29th International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024) (Business Wire) +8.70%
Feb-05-24 04:41PM	Revelation Biosciences Inc. Announces Closing of $6.2 Million Public Offering (Business Wire) +5.09% -18.75%
08:27AM	Loading…
Feb-01-24 08:27AM	Why Is Revelation Biosciences (REVB) Stock Down 62% Today? (InvestorPlace) -63.86%
06:00AM	Revelation Biosciences Inc. Announces Pricing of $6.2 Million Public Offering (Business Wire)
Jan-30-24 09:00AM	Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024) (Business Wire) -38.80%
Jan-29-24 08:26AM	Why Is Revelation Biosciences (REVB) Stock Up 61% Today? (InvestorPlace) +31.66%
Jan-23-24 09:00AM	Revelation Biosciences Inc. Announces 1-for-30 Reverse Stock Split Effective January 25, 2024 (Business Wire) -21.38%
Nov-13-23 04:05PM	Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2023 (Business Wire) +7.89%
Oct-12-23 09:00AM	Gemini Induces Pharmacologic Activity and Related Physiologic Changes in Multiple Preclinical Studies (Business Wire)
Oct-04-23 09:00AM	Revelation Biosciences, Inc. to Present at the 2023 ROTH Healthcare Opportunities Conference (Business Wire)
Oct-02-23 09:00AM	Revelation Biosciences Inc. Announces Appointment of Lakhmir Chawla, M.D. to Board of Directors (Business Wire)
Aug-14-23 07:36AM	REVB Reports Solid Balance Sheet and Remains on Track (Zacks)
Aug-11-23 04:10PM	Revelation Biosciences Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2023 (Business Wire)
Jun-29-23 09:00AM	REMINDER: Revelation Biosciences, Inc. Urges All Stockholders to Vote at the 2023 Annual Meeting of Stockholders (Business Wire)
Jun-22-23 10:24AM	REVB: REVB Looks Attractive Ahead of Trials (Zacks Small Cap Research)
Jun-12-23 04:15PM	Revelation Biosciences Inc. Announces Adjournment of 2023 Annual Meeting of Stockholders to July 7, 2023 and Additional Proposal (Business Wire)
May-22-23 09:00AM	Revelation Biosciences Inc. Announces Financial Results for the Three Months Ended March 31, 2023 and Recent Corporate Progress (Business Wire) +7.21%
05:42PM	Loading…
Mar-30-23 05:42PM	Revelation Biosciences Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2022 and Recent Corporate Progress (Business Wire)
Mar-13-23 09:00AM	Revelation Biosciences Inc. Appoints Dr. Julia Bohannon and Dr. Antonio Hernandez to Scientific Advisory Board (Business Wire)
Mar-06-23 09:00AM	Revelation Biosciences Inc. to Participate in a Fireside Chat at the 35th Annual Roth Conference (Business Wire)
Feb-13-23 04:20PM	Revelation Biosciences Inc. Announces Closing of $15.6 Million Public Offering (Business Wire) -5.59%
Feb-09-23 09:42AM	Revelation Biosciences Inc. Announces Pricing of $15.6 Million Public Offering (Business Wire) -48.51%
Feb-07-23 09:00AM	Revelation Biosciences Inc. Announces Preclinical Biomarker Data Supporting Activity of REVTx-300 (Business Wire) -22.65%
Jan-31-23 12:00PM	Revelation Biosciences Inc. Announces 1-for-35 Reverse Stock Split effective February 1, 2023 and Results of Special Meeting of Stockholders (Business Wire) +5.26%
Jan-10-23 09:00AM	Revelation Biosciences Inc. Announces Mandatory Unit Separation to Occur on January 13, 2023 (Business Wire)
Nov-18-22 09:00AM	Revelation Biosciences Inc. Announces Future Clinical Development Plans Based on Recent Biomarker Analysis and Significant Reduction in New Collagen Deposition (Fibrosis) in Preclinical Model (Business Wire)
Nov-10-22 04:30PM	Revelation Biosciences Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2022 and Recent Corporate Progress (Business Wire) +7.79%
Oct-25-22 11:13AM	Revelation Biosciences Inc. Announces Positive Results in Preclinical Model of Acute and Chronic Kidney Disease (Business Wire) +64.60%
Oct-06-22 07:00AM	Revelation Biosciences Inc. and Vanderbilt University Enter Exclusive Worldwide License Agreement (Business Wire) +14.44%
Aug-15-22 05:30PM	Revelation Biosciences Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2022 and Recent Corporate Progress (GlobeNewswire) -5.76%
Jul-29-22 11:45AM	Revelation Biosciences Inc. Announces Closing of $5 Million Public Offering (GlobeNewswire) -6.10%
Jul-26-22 08:15AM	Revelation Biosciences Inc. Announces Pricing of $5 Million Public Offering (GlobeNewswire) -51.39%
Jul-22-22 06:30PM	Revelation Biosciences Inc. Announces Topline Data for Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis (GlobeNewswire) -23.04% +55.38%
Jul-14-22 09:00AM	Revelation Biosciences Inc. Completes Database Lock for its Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis (GlobeNewswire) +16.10%
Jun-13-22 09:00AM	Revelation Biosciences Inc. Announces Completion of Dosing for a Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis (GlobeNewswire) -12.73%
May-23-22 09:00AM	Revelation Biosciences Inc. Announces Safety Monitoring Committee Recommendation for Continuing Evaluation of REVTx-99b for the Treatment of Allergic Rhinitis (GlobeNewswire)
May-16-22 04:01PM	Revelation Biosciences Inc. Announces Financial Results for the Three Months Ended March 31, 2022 and Recent Corporate Progress (GlobeNewswire)
Apr-06-22 09:00AM	Revelation Biosciences Inc. Announces Conference Call to Provide a Corporate Update (GlobeNewswire)
Mar-30-22 09:00AM	Revelation Biosciences Inc. Announces Primary Endpoint Analysis for Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx-99a for the Prevention of H3N2 Influenza Infection (GlobeNewswire) -38.32%
Mar-24-22 09:00AM	Revelation Biosciences Inc. Outlines Details on the Upcoming Data Analysis for Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx 99a for the Prevention of H3N2 Influenza Infection (GlobeNewswire) +11.94%
Mar-22-22 09:00AM	Revelation Biosciences Inc. to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC (GlobeNewswire) +6.54%
Mar-15-22 09:00AM	Revelation Biosciences Inc. Announces Enrollment and Dosing Complete for Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx 99 for the Prevention of H3N2 Influenza Infection (GlobeNewswire) +22.55%
Mar-08-22 09:00AM	Revelation Biosciences Inc. to Present at the 34th Annual Roth Conference (GlobeNewswire)
Feb-07-22 09:00AM	Revelation Biosciences Inc. to Present at 2022 BIO CEO & Investor Conference (GlobeNewswire) +9.58%
Jan-24-22 08:00AM	Revelation Biosciences Raises $7.76 Million in Equity Financing (GlobeNewswire) -19.15%
Jan-20-22 09:00AM	Revelation Biosciences Inc. Announces First Group of Patients Dosed in Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx-99 for the Prevention of H3N2 Influenza Infection (GlobeNewswire) -18.50%
Jan-18-22 09:00AM	Revelation Biosciences Inc. Announces First Patient Enrolled and Dosed in Phase 1b Clinical Study of REVTx-99 for the Treatment of Allergic Rhinitis (GlobeNewswire) -27.25%
Jan-13-22 01:54PM	REPEAT -- Revelation Biosciences Inc. Announces Data Demonstrating REVTx-99 In Vitro Anti-Viral Activity Against SARS-CoV-2; Commencement of Trading as a Public Company (GlobeNewswire) -19.03%

Revelation Biosciences, Inc. is a clinical-stage life sciences company, which focuses on the development of immunologic-based therapies for the prevention and treatment of disease. Its product candidates include REVTx-99b, its lead therapeutic candidate being developed for allergic rhinitis and chronic nasal congestion, REVDx 501, a rapid home use diagnostic that can be used to detect any respiratory viral infection, regardless of virus type or strain, without the need for specialized instrumentation, and REVTx 200, an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. The company was founded on November 20, 2019 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
TIDMARSH GEORGE F	Director	Dec 08 '23	Sale	0.52	27,771	14,438	0	Dec 12 04:48 PM
TIDMARSH GEORGE F	Director	Oct 16 '23	Sale	0.65	1,845	1,199	27,771	Oct 18 05:15 PM
TIDMARSH GEORGE F	Director	Oct 16 '23	Sale	0.66	10,957	7,243	42,096	Oct 17 04:12 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

REVB

Revelation Biosciences Inc

Upgrade your FINVIZ experience